Please use this identifier to cite or link to this item: https://apo.ansto.gov.au/dspace/handle/10238/3043
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKas, Aen_AU
dc.contributor.authorBottlaender, MAen_AU
dc.contributor.authorGallezot, JDen_AU
dc.contributor.authorVidailhet, Men_AU
dc.contributor.authorVillafane, Gen_AU
dc.contributor.authorGregoire, MCen_AU
dc.contributor.authorCoulon, CMen_AU
dc.contributor.authorValette, Hen_AU
dc.contributor.authorDolle, Fen_AU
dc.contributor.authorRibeiro, MJen_AU
dc.contributor.authorHantraye, Pen_AU
dc.contributor.authorRemy, Pen_AU
dc.date.accessioned2010-04-06T04:06:19Zen_AU
dc.date.accessioned2010-04-30T05:09:04Z-
dc.date.available2010-04-06T04:06:19Zen_AU
dc.date.available2010-04-30T05:09:04Z-
dc.date.issued2009-09en_AU
dc.identifier.citationKas, A., Bottlaender, M., Gallezot, J. D., Vidailhet, M., Villafane, G., Gregoire, M. C., Coulon. C., Valette, H., Dolle, F., Ribeiro, M. J., Hantrayne, P., & Remy, P. (2009). Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease. Journal of Cerebral Blood Flow and Metabolism, 29(9), 1601-1608. doi:10.1038/jcbfm.2009.74en_AU
dc.identifier.govdoc1584-
dc.identifier.issn0271-678Xen_AU
dc.identifier.urihttp://dx.doi.org/10.1038/jcbfm.2009.74en_AU
dc.identifier.urihttp://apo.ansto.gov.au/dspace/handle/10238/3043en_AU
dc.description.abstractSmoking is associated with a lower incidence of Parkinson's disease (PD), which might be related to a neuroprotective action of nicotine. Postmortem studies have shown a decrease of cerebral nicotinic acetylcholine receptors (nAChRs) in PD. In this study, we evaluated the decrease of nAChRs in PD in vivo using positron emission tomography (PET), and we explored the relationship between nAChRs density and PD severity using both clinical scores and the measurement of striatal dopaminergic function. Thirteen nondemented patients with PD underwent two PET scans, one with 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine (6-[18F]fluoro-L-DOPA) to measure the dopaminergic function and another with 2-[18F]fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine (2-[18F]fluoro-A-85380), a radiotracer with high affinity for the nAChRs. Distribution volumes (DVs) of 2-[18F]fluoro-A-85380 measured in the PD group were compared with those obtained from six nonsmoking healthy controls, with regions-of-interest and voxel-based approaches. Both analyses showed a significant (P <0.05) decrease of 2-[18F]fluoro-A-85380 DV in the striatum (−10%) and substantia nigra (−14.9%) in PD patients. Despite the wide range of PD stages, no correlation was found between DV and the clinical and PET markers of PD severity. © 2009, Nature Publishing Group.en_AU
dc.language.isoenen_AU
dc.publisherNature Publishing Groupen_AU
dc.subjectTobacco Smokesen_AU
dc.subjectPositron computed tomographyen_AU
dc.subjectDiseasesen_AU
dc.subjectPatientsen_AU
dc.subjectNicotineen_AU
dc.subjectReceptorsen_AU
dc.titleDecrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease.en_AU
dc.typeJournal Articleen_AU
dc.date.statistics2009-09en_AU
Appears in Collections:Journal Articles

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.